太平洋给予开立医疗买入评级：Q2业绩环比改善，看好未来持续修复

Group 1 - The core viewpoint of the report is that Kaili Medical (300633.SZ) is rated as a "buy" due to expected revenue recovery driven by increased equipment procurement [1] - The report highlights that the company is entering a "product year" as research and development investments are starting to yield results [1] - It notes that the gross margin is influenced by multiple factors, including ongoing increases in R&D and marketing expenditures [1]